ulcerative colitis
Conditions
Interventions
Experimental group:Mesalazine enteric-coated tablets combined with Quyushengxin formula
Control group:Mesalazine enteric-coated tablets
Sponsors
Yueyang Hospital of Integrated Chinese and Western Medicine affiliated to Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Patients with mild and moderate active stage who meet the diagnostic criteria of UC Western medicine, and TCM syndrome differentiation are large intestine damp-heat syndrome; (2) Age =18 and =65 years old, male or female; (3) Patients who have not received other medications for ulcerative colitis within 2 months; (4) The patient had good compliance, could adhere to regular medication follow-up, and signed informed consent.
Exclusion criteria
Exclusion criteria: (1) Pregnant or lactating women, allergic constitution and drug allergy involved in this study; (2) Patients with serious primary diseases of cardiovascular, cerebrovascular, liver, kidney and hematopoietic system and mental illness; (3) Patients with complications such as local intestinal stenosis, intestinal obstruction, intestinal perforation, rectal polyps, and colorectal cancer.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall apparent efficiency; | — |
Secondary
| Measure | Time frame |
|---|---|
| TCM syndrome integral;Improved classification of Truelove-Witts disease severity;Fecal bile acid concentration;Laboratory index (IL-1ßIL-6TNF-aESRHb); | — |
Countries
China
Contacts
Public ContactWang Zhenyi
Yueyang Hospital of Integrated Chinese and Western Medicine affiliated to Shanghai University of Traditional Chinese Medicine
Outcome results
None listed